A groundbreaking alliance between Worldwide Clinical Trials (Worldwide), Centrum Badan Klinicznych PI-House, and the Polish Psychedelic Society (PTP) aims to establish Poland as a leading center for psychedelic research. This collaboration stems from Poland’s first industry-sponsored psychedelic study supported by Worldwide.
The partnership was unveiled at the “Nauka Psychodeliczna” conference, where over 500 experts gathered to discuss the potential of psychedelics for mental health treatment. PTP president Maciej Lorenc emphasized the importance of Poland’s role in this field due to its experienced psychiatrists and patient base seeking innovative treatments.
Worldwide, a global CRO, has been a staunch advocate for psychedelic research since 2017. Bartosz Janikowski, Senior Vice President of Medical Sciences, stated that Worldwide is fully committed to advancing psychedelic research and collaborating with strategic partners like PI-House and PTP.
PI-House has a long history in psychiatric research and is now focusing on psychedelic treatments. Guided by Dr. Hanna Badzio-Jagiełło, the site has completed numerous psychiatric studies and has enhanced its infrastructure and training to meet the demands of psychedelic research.
PTP aims to promote research and collaboration on psychedelics within the global scientific community. The society’s goal is to gather knowledge and share it across borders to accelerate advancements in psychiatry and beyond.
This collaboration has created a dynamic research network in Poland that seeks to advance psychiatric treatments and explore the potential of psychedelics for mental health. Poland’s emergence as a psychedelic research hub will contribute to the advancement of innovative therapies for those suffering from mental health conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
